CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors and neuropathic pain, announced today that the first patient has been enrolled in a Phase 1b clinical trial with Yale University using the company’s T-type calcium channel drug mibefradil. The trial will introduce a new therapeutic approach to patients with recurrent glioblastoma multiforme (GBM).
The trial is an open label, dose-escalation study that will assess the safety and determine the maximum tolerated dose of mibefradil dihydrochloride, a repositioned anti-hypertensive T-type calcium channel blocker, combined with hypofractionated radiation therapy in subjects with recurrent GBM.
Help employers find you! Check out all the jobs and post your resume.
